Chugai Seiyaku Kabushiki Kaisha

Chugai Pharmaceutical Co.

Chugai Seiyaku Kabushiki

Koh Sato

Masayuki Tsuchiya

Kouji Matsushima

Yoshiki Yamada

Tatsumi Yamazaki

Naohiro Yabuta

Yoshihiro Matsumoto

Jose William Saldanha

Yuichi Hirata

Steven Tarran Jones

Mary M Bendig

Yuji Wakahara

Toshihiko Ohtomo

Hideki Adachi

Toshiaki Tsunenari

Kimie Ishii

Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.

Antibodies against human parathyroid hormone related protein

The present invention discloses reshaped antibody to human medulloblastoma cells comprising: Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

Reshaped human antibody to human medulloblastoma cells

A humanized antibody against tissue factor (TF), comprising: A: a humanized H chain comprising (1) a H chain V region comprising the H chain CDRs of a mouse monoclonal antibody against TF and the H chain FRs of a human antibody, and (2) the H chain C region of a human antibody; and B: a humanized L chain comprising (1) an L chain V region comprising the L chain CDRs of a mouse monoclonal antibody against TF and the L chain FRs of a human antibody, and (2) the L chain C region of a human antibody. After generating a humanized V region by grafting the CDRs of a mouse monoclonal antibody onto a human antibody, a humanized antibody having a higher activity is searched by replacing the FR of the above region with the corresponding FR of the human antibody having a high homology.

Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody

A reshaped human antibody to the human IL-6R, comprising: Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.

Reshaped human antibody to human interleukin-6 receptor

The invention relates to a therapeutic agent for cachexia comprising, as an active ingredient, a substance capable of inhibiting the binding between a parathyroid hormone related protein (PTHrP) and a receptor thereof.

Therapeutic agent for cachexia

Antibody against human parathormone related peptides

The present invention relates to a human/mouse chimeric antibody that includes the variable region of a mouse monoclonal antibody against human tissue factor (TF) and the constant region of a human antibody. The humanized antibody contains light and heavy chain complementarity determining regions of a mouse monoclonal antibody against human TF which have been grafted onto a human antibody. The present invention also provides a therapeutic agent for disseminated intravascular coagulation (DIC) syndrome, which includes a humanized antibody against human TF as an active ingredient.

A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

Reshaped human antibody to human interleukin-8

Reshaped human antibody to human interleukin-6

Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Growing community of inventors

Gotenba, Japan

Koh Sato